ARTICLE | Clinical News
M118: Phase I data
August 4, 2008 7:00 AM UTC
Momenta Pharmaceuticals Inc. (NASDAQ:MNTA), Cambridge, Mass. Product: M118 Business: Cardiovascular Molecular target: Thrombin; Anti-thrombin III (AT3) (SERPINC1) Description: Engineered low molecula...